These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 34089033)

  • 1. Antibody-laden nasal spray could provide COVID protection - and treatment.
    Kwon D
    Nature; 2021 Jun; ():. PubMed ID: 34089033
    [No Abstract]   [Full Text] [Related]  

  • 2. Nasal Spray of Neutralizing Monoclonal Antibody 35B5 Confers Potential Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Small-Scale Clinical Trial.
    Lin Y; Yue S; Yang Y; Yang S; Pan Z; Yang X; Gao L; Zhou J; Li Z; Hu L; Tang J; Wu Q; Lei S; Tian Q; Wang Y; Hao Y; Xu L; Huang Q; Zhu B; Chen Y; Chen X; Ye L
    Clin Infect Dis; 2023 Feb; 76(3):e336-e341. PubMed ID: 35666466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Neuroinvasion by SARS-CoV-2: Emerging Trends in Drug and Antibody Delivery to Combat COVID-19.
    Baig AM
    ACS Chem Neurosci; 2021 Jul; 12(14):2555-2557. PubMed ID: 34228437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China.
    Liu Y; Zhang J; Liu W; Pan Y; Ruan S; Nian X; Chen W; Sun L; Yin Q; Yue X; Li Q; Gui F; Wu C; Wang S; Yang Y; Jing Z; Long F; Wang Z; Zhang Z; Huang C; Duan K; Liang M; Yang X
    Emerg Microbes Infect; 2024 Dec; 13(1):2284297. PubMed ID: 37970736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nasal spray of an IgM-like ACE2 fusion protein HH-120 accelerates SARS-CoV-2 clearance: A single-center propensity score-matched cohort study.
    Song R; Chen X; Li B; Zhang H; Guo X; Liu Z; Zou L; Liang X; Lei C; Mao F; Sui J; Li W; Jin R
    J Med Virol; 2023 May; 95(5):e28805. PubMed ID: 37227062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice.
    Paull JRA; Luscombe CA; Castellarnau A; Heery GP; Bobardt MD; Gallay PA
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Povidone Iodine (PVP-I) Oro-Nasal Spray: An Effective Shield for COVID-19 Protection for Health Care Worker (HCW), for all.
    Arefin MK
    Indian J Otolaryngol Head Neck Surg; 2022 Oct; 74(Suppl 2):2906-2911. PubMed ID: 33846691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of safety and intranasal neutralizing antibodies of HPMC-based human anti-SARS-CoV-2 IgG1 nasal spray in healthy volunteers.
    Imsuwansri T; Jongthitinon T; Pojdoung N; Meesiripan N; Sakarin S; Boonkrai C; Wongtangprasert T; Phakham T; Audomsun T; Attakitbancha C; Saelao P; Muanwien P; Tian MT; Tongchusak S; Sangruji B; Wannigama DL; Sawangmake C; Rodprasert W; Le QD; Purbantoro SD; Vasuntrarak K; Nantavisai S; Sirilak S; Uppapong B; Sapsutthipas S; Trisiriwanich S; Somporn T; Usoo A; Mingngamsup N; Phumiamorn S; Aumklad P; Arunprasert K; Patrojanasophon P; Opanasopit P; Pesirikan N; Nitisaporn L; Pitchayakorn J; Narkthong T; Mahong B; Chaiyo K; Srisutthisamphan K; Viriyakitkosol R; Aeumjaturapat S; Jongkaewwattana A; Bunnag S; Pisitkun T
    Sci Rep; 2023 Sep; 13(1):15648. PubMed ID: 37730833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-Free Nasal Spray as a Barrier against SARS-CoV-2 and Its Delta Variant: In Vitro Study of Safety and Efficacy in Human Nasal Airway Epithelia.
    Fais F; Juskeviciene R; Francardo V; Mateos S; Guyard M; Viollet C; Constant S; Borelli M; Hohenfeld IP
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Negativization of SARS-CoV-2 Infection by Nasal Spray of Seawater plus Additives: The RENAISSANCE Open-Label Controlled Clinical Trial.
    Cegolon L; Mastrangelo G; Emanuelli E; Camerotto R; Spinato G; Frezza D
    Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432693
    [No Abstract]   [Full Text] [Related]  

  • 11. Post-exposure prophylaxis with SA58 (anti-SARS-COV-2 monoclonal antibody) nasal spray for the prevention of symptomatic COVID-19 in healthy adult workers: a randomized, single-blind, placebo-controlled clinical study.
    Song R; Zeng G; Yu J; Meng X; Chen X; Li J; Xie X; Lian X; Zhang Z; Cao Y; Yin W; Jin R
    Emerg Microbes Infect; 2023 Dec; 12(1):2212806. PubMed ID: 37157134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralisation of SARS-CoV-2 by monoclonal antibody through dual targeting powder formulation.
    Seow HC; Cai JP; Pan HW; Luo C; Wen K; Situ J; Wang K; Cao H; Leung SWS; Yuan S; Lam JKW
    J Control Release; 2023 Jun; 358():128-141. PubMed ID: 37084889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporine A micellar nasal spray characterization and antiviral action against SARS-CoV-2.
    Guareschi F; Del Favero E; Ricci C; Cantù L; Brandolini M; Sambri V; Nicoli S; Pescina S; D'Angelo D; Rossi I; Buttini F; Bettini R; Sonvico F
    Eur J Pharm Sci; 2024 Feb; 193():106673. PubMed ID: 38103657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Pilot Study of 0.4% Povidone-Iodine Nasal Spray to Eradicate SARS-CoV-2 in the Nasopharynx.
    Sirijatuphat R; Leelarasamee A; Puangpet T; Thitithanyanont A
    Infect Drug Resist; 2022; 15():7529-7536. PubMed ID: 36575672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cluster randomised, controlled, triple-blind trial assessing the efficacy of intranasally administered virus-neutralising bovine colostrum supplement in preventing SARS-CoV-2 infection in household contacts of SARS-CoV-2-positive individuals: a study protocol.
    Uusküla A; Keis A; Toompere K; Planken A; Rebrov K
    Trials; 2022 Jan; 23(1):92. PubMed ID: 35101094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world effectiveness of an intranasal spray A8G6 antibody cocktail in the post-exposure prophylaxis of COVID-19.
    Li X; Peng P; Deng H; Yang Q; Chen S; Li B; He M; Jin A; Yang Z; Tang N; Huang A
    Signal Transduct Target Ther; 2023 Oct; 8(1):403. PubMed ID: 37867182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection.
    Winchester S; John S; Jabbar K; John I
    J Infect; 2021 Aug; 83(2):237-279. PubMed ID: 33992687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitric Oxide and its Derivatives Containing Nasal Spray and Inhalation Therapy for the Treatment of COVID-19.
    Chavda VP; Patel AB; Vora LK; Singla RK; Shah P; Uversky VN; Apostolopoulos V
    Curr Pharm Des; 2022; 28(46):3658-3670. PubMed ID: 36284382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ColdZyme Maintains Integrity in SARS-CoV-2-Infected Airway Epithelia.
    Posch W; Vosper J; Zaderer V; Noureen A; Constant S; Bellmann-Weiler R; Lass-Flörl C; Wilflingseder D
    mBio; 2021 Apr; 12(2):. PubMed ID: 33906927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Povidone-Iodine Nasal Spray on Nasopharyngeal SARS-CoV-2 Viral Load: A Randomized Control Trial.
    Zarabanda D; Vukkadala N; Phillips KM; Qian ZJ; Mfuh KO; Hatter MJ; Lee IT; Rao VK; Hwang PH; Domb G; Patel ZM; Pinsky BA; Nayak JV
    Laryngoscope; 2022 Nov; 132(11):2089-2095. PubMed ID: 34724213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.